STAAR Surgical Company filings document the regulatory record for a NASDAQ-listed ophthalmic device company focused on phakic IOLs and the EVO family of Implantable Collamer® Lenses. Its reports and exhibits cover operating results, preliminary sales disclosures, shareholder letters, product and market commentary, and clinical or regulatory matters tied to lens-based vision correction.
Recent filings also address proxy and governance disclosure, shareholder voting matters, board and committee composition, director independence, executive appointments and separation arrangements, material agreements, capital-structure disclosure for common stock, and the termination of a previously disclosed merger agreement.
STAAR Surgical President and CEO Warren Foust reported the vesting and conversion of 20,787 Restricted Stock Units granted on February 2, 2026 in connection with his appointment as Interim Co-Chief Executive Officer. These RSUs vested on July 31, 2026 and converted into common stock on a one-for-one basis. To satisfy obligations associated with this vesting, 10,576 common shares were withheld at $24.36 per share. A footnote also corrects an earlier Form 4, stating his beneficial ownership was 76,345 shares rather than 83,112 in that prior report.
STAAR Surgical reports equity award activity for Chief Financial Officer & EVP Deborah J. Andrews. On June 25 and July 31, 2026, previously granted RSUs vested, converting into a total of 34742 shares of common stock. In related code F transactions, 6480 shares at $31.2100 and 10576 shares at $24.3600 per share were disposed of to pay exercise price or tax liability, with no open-market purchases or sales reported.
STAAR Surgical director Christopher Min Fang Wang received a grant of stock options, acquiring rights to 11,145 shares of common stock. The options have an exercise price of $29.12 per share and were granted as compensation, not through open-market buying or selling.
These options vest in full on the earlier of June 18, 2027 or the company’s 2026 annual meeting of shareholders, and expire on June 18, 2036. After this grant, Wang holds 11,145 options directly under this award.
STAAR Surgical director Richard T. LeBuhn received a new stock option grant as part of his director compensation. He was granted options covering 11,145 shares of common stock at an exercise price of $29.12 per share, with no cash paid for the grant.
These options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, subject to his continuous service. LeBuhn also holds previously granted options covering 7,524 shares at an exercise price of $18.46 per share that are currently exercisable and expire in 2036.
STAAR Surgical director Neal C. Bradsher reported a new stock option grant as director compensation. He received options for 11,145 shares of common stock at an exercise price of $29.12 per share, expiring on June 18, 2036.
The new options will vest and become exercisable on the earlier of June 18, 2027 or the company’s next annual shareholder meeting after the grant date, contingent on his continued service. Bradsher also holds previously granted options covering 7,524 underlying shares at an exercise price of $18.46 per share, which are currently exercisable.
STAAR Surgical Company reported results from its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders approved Amendment No. 2 to the Amended and Restated Omnibus Equity Incentive Plan, increasing the shares of common stock reserved for issuance under the plan by 3,900,000 shares.
Seven directors were elected to serve until the 2027 annual meeting or until successors are elected and qualified. Shareholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the fiscal year ending January 1, 2027 and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. As of April 20, 2026, there were 49,788,295 outstanding common shares, and a quorum of 43,680,435 shares was represented at the meeting.
STAAR Surgical director Arthur C. Butcher exercised 5,341 restricted stock units into Common Stock on June 18, 2026, bringing his direct Common Stock holdings to 9,549 shares.
He also received 3,709 new restricted stock units and 4,458 stock options at a $29.12 exercise price, which vest in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Shareholders.
Zhou Lilian Yansheng reported acquisition or exercise transactions in this Form 4 filing.
STAAR Surgical director Lilian Yansheng Zhou received new equity awards as part of the company’s annual non-employee director compensation for the 2026-2027 term. On June 18, 2026, Zhou was granted options to purchase 5,572 shares of common stock at $29.12 per share, expiring June 17, 2036.
Zhou also received 3,091 restricted stock units tied to common stock. According to the grant terms, both the options and the restricted stock units vest in full on the earlier of June 18, 2027 or STAAR Surgical’s 2027 Annual Meeting of Shareholders.
STAAR Surgical director Lou Silverman reported compensation-related equity activity. He exercised 10,683 previously granted restricted stock units into an equal number of common shares and now directly holds 11,158 shares. On the same date, he received a new grant of 6,182 restricted stock units for the 2026–2027 non‑employee director term, which will vest in full on the earlier of June 18, 2027 or the company’s 2027 annual shareholder meeting. All transactions reflect equity awards and exercises rather than open‑market buying or selling.
STAAR Surgical director Jiang Wei reported equity compensation transactions involving company stock. On June 18, 2026, Jiang Wei exercised 10,683 previously granted restricted stock units into 10,683 shares of common stock, increasing direct common share holdings to 77,127 shares after the transactions.
On the same date, Jiang Wei received a new grant of 6,182 restricted stock units under the annual non-employee director equity compensation program for the 2026-2027 term. These new units are scheduled to vest in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Shareholders.